SAMN03290925
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.600
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- COMPLEMENT+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- PANCREAS_BETA_CELLS+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- KRAS_SIGNALING_DN+0.300
- XENOBIOTIC_METABOLISM+0.300
Top 10 suppressed
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.500
- MITOTIC_SPINDLE-0.500
- MYC_TARGETS_V1-0.400
- MYC_TARGETS_V2-0.400
- TGF_BETA_SIGNALING-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
- UV_RESPONSE_DN-0.400
- WNT_BETA_CATENIN_SIGNALING-0.400
- ANDROGEN_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A5XS-01A-11R-A29R-07 | — | B | 0.905 |
| 2 | da7cbc0a-95dc-4303-a5dd-75857c066f3b | — | — | 0.899 |
| 3 | f5760366-59eb-417d-a935-3f78e999dd42 | — | — | 0.894 |
| 4 | d3be84d5-9dd7-4366-9aea-532dc76f19ba | — | — | 0.890 |
| 5 | ERR2598268 | fetal | fetal | 0.883 |
| 6 | ERR2598328 | fetal | fetal | 0.876 |
| 7 | R238 | — | — | 0.873 |
| 8 | R13 | — | — | 0.871 |
| 9 | ERR2598280 | fetal | fetal | 0.869 |
| 10 | TCGA-E9-A5FK-01A-11R-A27Q-07 | — | B | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |